Candel Therapeutics has announced a significant $100 million royalty funding agreement with RTW Investments to facilitate the anticipated launch of its innovative therapy, aglatimagene besadenovec (CAN-2409), for localized prostate cancer. This strategic financing is designed to support the company’s commercial initiatives, contingent upon receiving approval from the FDA.
Non-Dilutive Financing Strategy
Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO of Candel, expressed confidence in this partnership, highlighting that the non-dilutive nature of the funding will enable the company to enhance its commercial program. Candel is on track to submit a Biologics License Application (BLA) for aglatimagene by the fourth quarter of this year. The company anticipates a productive collaboration with the FDA to expedite the approval process. Tak emphasized the importance of providing a new treatment option for patients battling early-stage prostate cancer, a field that has seen limited advancements in recent years.
Clinical Demonstration of Efficacy
The pivotal phase 3 clinical trial has showcased the potential effectiveness of aglatimagene besadenovec in treating early, localized prostate cancer. Roderick Wong, M.D., Managing Partner and Chief Investment Officer at RTW Investments, echoed this sentiment, stating that the firm’s commitment underscores their confidence in both Candel and the promising commercial prospects of this therapy. RTW looks forward to collaborating with Candel’s management team to make this vital treatment accessible to patients.
Royalty Agreement Details
The royalty financing will be activated upon FDA approval of aglatimagene and the fulfillment of standard conditions. According to the terms of the agreement, RTW will receive a tiered, single-digit percentage of annual net sales from aglatimagene in the United States, capped at a specified limit. This structure not only provides Candel with the necessary capital for launch but also aligns the interests of both parties in the therapy’s commercial success.
Candel’s Innovative Platforms
Candel Therapeutics is a clinical-stage biopharmaceutical firm dedicated to developing off-the-shelf multimodal biological immunotherapies. Their approach aims to generate a personalized, systemic anti-tumor immune response, enhancing the ability of patients to combat cancer. The company has established two clinical-stage platforms based on novel gene constructs from genetically modified adenoviruses and herpes simplex viruses (HSV).
Aglatimagene besadenovec is the flagship candidate from the adenovirus platform. Candel has recently completed successful phase 2a trials for this therapy in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). The pivotal phase 3 trial for localized prostate cancer was conducted under a Special Protocol Assessment with the FDA, which has granted Fast Track and Regenerative Medicine Advanced Therapy Designations for aglatimagene in various indications.
Ongoing Trials and Future Directions
Additionally, Candel’s linoserpaturev (CAN-3110), the lead candidate from the HSV platform, is currently being evaluated in an ongoing phase 1b clinical trial targeting recurrent high-grade glioma. Early results from this study have been published in prominent scientific journals, and linoserpaturev has also received Fast Track and Orphan Drug Designations from the FDA. Candel’s enLIGHTEN™ Discovery Platform further exemplifies their commitment to innovation, employing advanced analytics and human biology to develop new viral immunotherapies for solid tumors.
Strategic Importance of Investor Relationships
The partnership with RTW is a strategic move for Candel, providing essential funding while minimizing equity dilution. Such arrangements are increasingly vital in the biotech sector, where capital requirements for research and development can be substantial. By securing this agreement, Candel not only enhances its financial position but also strengthens its ability to focus on delivering groundbreaking therapies to patients.
Conclusion
Candel Therapeutics stands at the forefront of innovation in cancer treatment with its promising therapy, aglatimagene besadenovec. The recent $100 million royalty agreement with RTW Investments is a testament to the confidence in Candel’s potential to transform prostate cancer treatment. As the company moves closer to FDA approval, the collaboration positions Candel for a successful market entry, ultimately benefiting patients in need of new therapeutic options.
- Candel secures $100M funding for aglatimagene besadenovec.
- FDA approval is a key milestone for therapy launch.
- Collaboration with RTW enhances financial and strategic positioning.
- Candel’s innovative platforms show promise across multiple cancer types.
- The partnership exemplifies the importance of non-dilutive funding in biotech.
Read more → www.manilatimes.net